FDA Approves Leucovorin for Rare Genetic Disorder, Not Autism
The US Food and Drug Administration has approved leucovorin as the first drug indicated for cerebral folate deficiency, a rare genetic disorder, drawing a clear regulatory line around a treatment that the Trump administration had previously promoted as a potential therapy for autism.
The approval, confirmed on 10 March 2026, is specific to cerebral folate deficiency and does not extend to autism or broader autism-spectrum symptoms. That distinction is significant given that senior officials in the Trump administration had publicly touted leucovorin as a promising option for patients with autism symptoms in the months preceding the decision.
The FDA's move represents a notable moment of institutional restraint, with regulators confining the drug's sanctioned use to the narrow population for which clinical evidence was deemed sufficient. Cerebral folate deficiency is a rare genetic condition in which folate transport to the brain is impaired, leading to a range of neurological symptoms.
Leucovorin, a form of folinic acid, has now become the first drug formally approved to treat that condition, according to Forbes. The approval was reported by both Forbes and CNBC on the same day, with both outlets noting the backdrop of political commentary that had surrounded the drug.
CNBC reported that the Trump administration's promotion of leucovorin as a therapy for a broader group of patients with autism symptoms had preceded the FDA decision by several months, raising questions about the relationship between political signalling and the regulatory process. Forbes was direct in its framing, noting that the approval was granted for cerebral folate deficiency and explicitly not for autism, even after administration officials had spoken favourably of the drug in that context.
The episode underscores the tensions that can arise when public health officials comment on drugs that remain under regulatory review, particularly in cases involving conditions as politically and socially charged as autism. The FDA's approval, confined strictly to cerebral folate deficiency, reflects the agency's standard evidence-based framework, whatever the surrounding political environment.
